Mepenzolate
Cantil (mepenzolate) is a small molecule pharmaceutical. Mepenzolate was first approved as Cantil on 1982-01-01. It is used to treat peptic ulcer in the USA. It is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M3, and muscarinic acetylcholine receptor M4.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mepenzolate bromide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CANTIL | Sanofi | N-010679 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| peptic ulcer | HP_0004398 | D010437 | K27 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
269 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | 10 | 8 | 10 | 1 | 5 | 33 |
| Neuralgia | D009437 | EFO_0009430 | 1 | 6 | 2 | 2 | 7 | 17 | |
| Healthy volunteers/patients | — | 6 | 3 | — | 1 | 7 | 16 | ||
| Diabetic neuropathies | D003929 | EFO_1000783 | 1 | 5 | 6 | 2 | — | 11 | |
| Postherpetic neuralgia | D051474 | 1 | 2 | — | 3 | — | 5 | ||
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 2 | — | — | 1 | 1 | 4 |
| Peripheral nerve injuries | D059348 | 1 | 1 | — | 2 | — | 3 | ||
| Exercise | D015444 | EFO_0000483 | 1 | — | — | 2 | — | 3 | |
| Central nervous system sensitization | D059333 | 1 | — | — | 1 | — | 2 | ||
| Motor disorders | D000068079 | — | — | — | 1 | — | 1 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peripheral nervous system diseases | D010523 | G64 | — | 5 | 5 | — | 2 | 11 | |
| Cough | D003371 | HP_0012735 | R05 | 4 | 2 | 1 | — | 4 | 9 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 4 | 3 | — | — | 7 |
| Herpes zoster | D006562 | EFO_0006510 | B02 | — | 5 | 2 | — | — | 6 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 1 | — | 2 | 4 |
| Acute pain | D059787 | R52 | — | 1 | 1 | — | 2 | 4 | |
| Head and neck neoplasms | D006258 | — | 1 | 1 | — | — | 2 | ||
| Pharyngitis | D010612 | R07.0 | — | — | 2 | — | — | 2 | |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | 2 | — | — | 2 |
| Vulvodynia | D056650 | N94.81 | — | 1 | 1 | — | — | 1 |
Show 10 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Deglutition disorders | D003680 | HP_0002015 | R13.1 | — | 2 | — | — | 5 | 7 |
| Pruritus | D011537 | HP_0000989 | L29 | 1 | 1 | — | — | 5 | 6 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 2 | 1 | — | — | 1 | 3 |
| Vomiting | D014839 | HP_0002013 | R11.1 | — | 2 | — | — | 1 | 3 |
| Facial pain | D005157 | R51.9 | 1 | 1 | — | — | — | 2 | |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | 2 | — | — | — | 2 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | 1 | — | — | 1 | 2 | |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 2 | — | — | — | 2 |
| Polyneuropathies | D011115 | EFO_0009562 | A69.22 | — | 2 | — | — | — | 2 |
| Colonic neoplasms | D003110 | C18 | — | 1 | — | — | 1 | 2 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tobacco use disorder | D014029 | F17 | 2 | — | — | — | 6 | 8 | |
| Tobacco use | D064424 | Z72.0 | 1 | — | — | — | 4 | 5 | |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 2 | — | — | — | 2 | 4 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | — | — | — | 3 | 4 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 2 | — | — | — | 1 | 3 |
| Metabolism | D008660 | GO_0008152 | 2 | — | — | — | — | 2 | |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | — | — | — | — | 1 |
| Cluster headache | D003027 | HP_0012199 | G44.00 | 1 | — | — | — | — | 1 |
| Trigeminal autonomic cephalalgias | D051303 | 1 | — | — | — | — | 1 | ||
| Paroxysmal hemicrania | D051302 | EFO_1001822 | G44.03 | 1 | — | — | — | — | 1 |
Show 6 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dental caries | D003731 | EFO_0003819 | K02 | — | — | — | — | 10 | 10 |
| Vaping | D000072137 | — | — | — | — | 9 | 9 | ||
| Smoking | D012907 | EFO_0003768 | F17 | — | — | — | — | 6 | 6 |
| Thirst | D013894 | — | — | — | — | 4 | 4 | ||
| Hyperalgesia | D006930 | — | — | — | — | 3 | 3 | ||
| Tobacco smoking | D000073869 | — | — | — | — | 3 | 3 | ||
| Headache | D006261 | HP_0002315 | R51 | — | — | — | — | 2 | 2 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | — | 2 | 2 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | — | — | 2 | 2 |
| Chest pain | D002637 | HP_0100749 | R07.9 | — | — | — | — | 2 | 2 |
Show 48 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MEPENZOLATE |
| INN | mepenzolate bromide |
| Description | 2-hydroxy-2,2-diphenylacetic acid (1,1-dimethyl-3-piperidin-1-iumyl) ester is a diarylmethane. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[N+]1(C)CCCC(OC(=O)C(O)(c2ccccc2)c2ccccc2)C1 |
Identifiers
| PDB | — |
| CAS-ID | 25990-43-6 |
| RxCUI | 107770 |
| ChEMBL ID | CHEMBL524004 |
| ChEBI ID | — |
| PubChem CID | 4057 |
| DrugBank | DB04843 |
| UNII ID | APX8D32IX1 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CHRM2
CHRM2
CHRM3
CHRM3
CHRM4
CHRM4
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 132 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,691 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more